Is CJC-1295 with GHRP-2 legal in the United Kingdom?

A 10 mg vial split evenly between a GHRH analogue and a ghrelin-receptor agonist. The pairing of those two drug classes has genuine human data, including a study in which combining them drove more growth hormone than either alone, but that work used different agents, given intravenously or by pump, in a clinic. No study has tested this vial.

This is the oldest rationale in the growth hormone corner of the peptide market: hit the pituitary from two directions at once. A GHRH analogue raises the size of a pulse, a ghrelin-receptor agonist triggers one and blunts somatostatin, and the two together do more than either.

Mechanism: Two receptors, one axis. The GHRH analogue binds the GHRH receptor on pituitary somatotrophs and increases the amplitude of a growth hormone pulse.

Regulatory history: Not approved. Neither component is an approved medicine in the United States, and the combination has never been evaluated.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for CJC-1295 with GHRP-2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.